USD 12.66 billion
Recombinant Coagulation Factors Market Size, Share, Growth Analysis, By Product(Recombinant factor VIII, Recombinant factor IX, Von Willebrand factor), By Application(Hospitals, Clinics, Research Organizations), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2118 |
Region:
Global |
Published Date: April, 2024
Pages:
219
|Tables:
63
|Figures:
80
Recombinant Coagulation Factors Market Insights
Recombinant Coagulation Factors Market size was valued at USD 13.46 Billion in 2023 and is poised to grow from USD 14.31 Billion in 2024 to USD 23.32 Billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).
Recombinant coagulation factors are proteins that play a role in blood clotting. They are produced by recombinant DNA technology, in which genes for the desired protein are inserted into host cells, such as bacteria or yeast. The cells then express the protein, which can be purified and used for therapeutic purposes. These proteins treat patients with haemophilia and other bleeding disorders. Factor VIII (FVIII), factor IX (FIX), and von Willebrand factor (VWF), are several types of recombinant coagulation factors. Recombinant coagulation factors are plasma derivatives used to treat infections caused by viruses such as hepatitis C and human immunodeficiency virus. Also recombinant factors have a low risk of transmission of infectious agents.
Increasing incidence of haemophilia and other bleeding diseases, increasing consumer demand for plasma-derived and recombinant coagulation factors, increasing number of R&D on coagulation factors, and increasing number of product approvals for new recombinant coagulation factors are all contributing for expansion of this market. However, high cost treatment of haemophilia care and low cost treatment from plasma coagulation alternatives factor available to recombinant coagulation factors are hamper the growth of global market. Also, the expansion of this market is expected due to increasing prophylactic treatment for haemophilia worldwide.
US Recombinant Coagulation Factors Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Recombinant factor VIII
Fastest Growth
Recombinant factor VIII
Growth Rate
6.3% CAGR
Global recombinant coagulation factors market, 2022-2030 ($ Bn)
Country Share for North America Region- 2022 (%)
To get more reports on the above market click here to Buy The Report
Recombinant Coagulation Factors Market Segmental Analysis
Global recombinant coagulation factors market is based of products, haemophilia type and region. On the basis of products, global market is segmented into recombinant factor VIII, recombinant factor IX, and Von Willebrand factor. On the basis of application, global market is segmented into Hospitals, Clinics, and Research Organizations. On the basis of region, global market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
Analysis by Product
On the basis of products, global recombinant coagulation factors market is segmented into recombinant factor VIII, recombinant factor IX, and Von Willebrand factor. A protein called recombinant Factor VIII helps in blood clotting. The rare bleeding disorder haemophilia A, in which the blood does not clot properly, is treated with it. Factor VIII is created in a lab and is the same as the factor VIII found in healthy individuals. Without sufficient factor VIII, even a little wound can result in significant bleeding that can be difficult to treat. To replace the deficient factor VIII and help in the blood clotting, recombinant factor VIII is injected into a vein or muscle. Typically, it is only administered when necessary for surgery or bleeding. The recombinant factor VIII has the largest share of the global recombinant coagulation factor market. The large share of this segment is due to increasing number of haemophilia A patients and rising prophylaxis treatment.
A protein called recombinant Factor IX (rFIX) is used to treat or prevent bleeding in haemophilia B patients. rFIX works by increasing blood coagulation. This can reduce bleeding incidents and reduce the risk of severe bleeding-related problems. The Factor IX occurring naturally in the body is identical to rFIX, which is produced using recombinant DNA technology. It is administered as an intravenous infusion.
Blood contains the glycoprotein known as Von Willebrand Factor (VWF), which helps in controlling bleeding. Von Willebrand disease patients typically have higher VWF levels, while some other bleeding disorders may have lower levels. Genetic engineering is used to create recombinant VWF products, which are used to treat or prevent bleeding in patients with von Wille brand disease.
Analysis by Application
On the basis of application global recombinant coagulation factors market is segmented into Hospitals, Clinics, and Research Organizations. Hospital segment has the largest share of global recombinant coagulation factor market and is expected to grow at significant CAGR during forecast period. Recombinant coagulation factors are used in hospitals for the treatment of patients with haemophilia and other bleeding disorders. These factors help to control bleeding by replacing the missing or defective factor in the patient's blood. Recombinant Factor VIII is used to treat haemophilia A, which is caused by a deficiency of Factor VIII. Recombinant Factor IX is used to treat haemophilia B, which is caused by a deficiency of Factor IX.
To treat and prevent bleeding disorders, recombinant coagulation factors are used in clinics. These factors help to control bleeding by replacing missing or defective clotting factors in the blood. Coagulation disorders can be caused by genetic disorders and acquired disorders. Treatment with recombinant coagulation factors can improve the quality of life for people with bleeding disorders by reducing the frequency and severity of bleeds.
Global recombinant coagulation factors market, Size by Product, 2022 (%)
To get detailed analysis on other segments, Request For Free Sample Report
Recombinant Coagulation Factors Market Regional Insights
On the basis of region, global recombinant coagulation factors market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the global market during the forecast period. Increasing demand for treatment and rising patient awareness about different treatment options are driving the market in North America.
The Asia Pacific region is expected to grow at significant growth during the forecast period. Increasing medical tourism in developing countries, rising investments by market players in Asia Pacific, especially in India and China, and growing awareness about haemophilia treatment are likely to drive the market in Asia Pacific during the forecast period. Increasing incidence of haemophilia and other bleeding diseases, increasing consumer demand for plasma-derived and recombinant coagulation factors, increasing number of R&D on coagulation factors, and increasing number of product approvals for new recombinant coagulation factors are all contributing for expansion of global recombinant coagulation factors market.
Global recombinant coagulation factors market, by geography, 2022-2030
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Recombinant Coagulation Factors Market Dynamics
Driver
- Significant investment in research and development
The market has seen a consistent increase in R&D expenditure and funding in pharmaceutical and biotechnological sector throughout the period. The key players in the market are significantly invested in research and development of technologically advanced products leading to increased utilization of the Recombinant Coagulation Factors products across developed and developing countries of the world, that drive the growth of global recombinant coagulation factors market. Increasing number of product approvals for new recombinant coagulation factors is one of the major factor responsible for market expansion.
Restraint
- High cost of treatment and alternative factor available for recombinant coagulation
High cost treatment of haemophilia care and low cost treatment of plasma coagulation is available in market. Also, alternative factors are available to recombinant coagulation factors are hamper the growth of global recombinant coagulation factors market.
- Limited disease awareness
Limited disease awareness is one of major factor that hamper the growth of global recombinant coagulation factor market. Recombinant coagulation factor products are not widely used in developing countries of the world due to high production costs, poor economic conditions and unfavourable health care systems.
Request Free Customization of this report to help us to meet your business objectives.
Recombinant Coagulation Factors Market Competitive Landscape
There are several major players in global recombinant coagulation factors market. Several strategies are used by major market players to survive in the competition, such as mergers & acquisitions, partnerships, new product launches, and collaborations.
Top Player's Company Profiles
- Novo Nordisk A/S
- Shire plc
- CSL Behring
- Sanofi S.A.
- Pfizer Inc.
- Bayer AG
- Biogen Inc.
- Grifols, S.A.
- Kedrion S.p.A.
- Octapharma AG
- Green Cross Corporation
- Baxalta (now part of Takeda Pharmaceutical Company Limited)
- LFB S.A.
- Genzyme Corporation (now part of Sanofi S.A.)
- Bioverativ Inc. (now part of Sanofi S.A.)
- Swedish Orphan Biovitrum AB (publ)
- BDI Pharma, Inc.
- Emergent BioSolutions Inc.
- Prometic Life Sciences Inc.
- Albumedix Ltd.
Recent Developments
- In June 2023, Thermo Fisher Scientific developed a new biologics manufacturing facility in Lengnau, in the Swiss canton of Bern, to improve its pharmaceutical services capacity and manufacturing capabilities to meet the growing demand for biologic therapies.
- In May 2022, Takeda Pharmaceutical Co Ltd announced the expansion of its rare diseases portfolio in India with the launch of Adynovate, used in the treatment of hemophilia.
- In May 2022, Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, announced the launch of its new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities.
- In September 2021, Octapharma announced that the European Commission had granted marketing authorization for its recombinant human von Willebrand factor / recombinant human coagulation factor VIII (rVWF/rFVIII) concentrate, Wilfactin®. This product is indicated for the treatment and prevention of bleeding in patients with von Willebrand disease.
- In August 2021, Pfizer acquired Amplyx Pharmaceuticals, which gives Pfizer access to Amplyx's portfolio of antifungal compounds, including the recombinant factor H-related protein 1 (CFHR1). CFHR1 is being developed as a potential treatment for severe fungal infections in patients with compromised immune systems.
Recombinant Coagulation Factors Key Market Trends
- Rising impact of blood disorders and growing adoption of recombinant coagulation factors are key trend that drive the global recombinant coagulation factors market. Recombinant coagulation factor is a type of blood factor produced by recombinant technology. It is used in the treatment of disorders such as haemophilia.
- Increasing research and development expenditure on recombinant coagulation factors development is the key industry trend for the recombinant coagulation factors market. Leading players in the market focus on developing cost-effective and high-quality products for addressing opportunities in developing regions. This is reflected in the increasing expenditure on research and development and the increasing number of new product approvals.
Recombinant Coagulation Factors Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our business information services team that collects, collates, co-relates, and analyses the data collected by means of primary exploratory research backed by the robust secondary desk research.
According to our global recombinant coagulation factors market analysis, the recombinant factor VIII has the largest share of the global market due to increasing number of haemophilia A patients and rising prophylaxis treatment. North America is expected to dominate the global market. Increasing demand for treatment and rising patient awareness about different treatment options are the factors responsible for market growth in North America. High cost of treatment, alternative factor available for recombinant coagulation, limited disease awareness, high production costs, poor economic conditions and unfavourable health care systems are the factors that hamper the market growth.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 12.66 billion |
| Market size value in 2031 | USD 21.94 billion |
| Growth Rate | 6.3% |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
Recent Developments
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Recombinant Coagulation Factors Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Recombinant Coagulation Factors Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Recombinant Coagulation Factors Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Recombinant Coagulation Factors Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Recombinant Coagulation Factors Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Recombinant Coagulation Factors Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
